Zobrazeno 1 - 10
of 106
pro vyhledávání: '"Courtney D. Fitzhugh"'
Autor:
Ahmad Shaikh, Arunakumar Gangaplara, Abdoul Kone, Katherine Almengo, Mariama D. Kabore, Mohamed A.E. Ali, Xin Xu, Ankit Saxena, Maria Lopez-Ocasio, J. Philip McCoy, Courtney D. Fitzhugh
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Haploidentical hematopoietic cell transplantation (haplo-HCT) is associated with an increased risk of allograft rejection. Here, we employed a major histocompatibility complex (MHC)-mismatched allogeneic HCT (allo-HCT) murine model to better understa
Externí odkaz:
https://doaj.org/article/24e35174d94942e4b4ebfeee39393ccf
Autor:
Lyra Morina, Madalyn E. Jones, Cihan Oguz, Mariana J. Kaplan, Arunakumar Gangaplara, Courtney D. Fitzhugh, Christopher G. Kanakry, Ethan M. Shevach, Maja Buszko
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Foxp3 is regarded as the major transcription factor for T regulatory (Treg) cells and expression of Foxp3 is used to identify and quantitate Treg cells in mouse models. However, several studies have demonstrated that human CD4+ T conventional (Tconv)
Externí odkaz:
https://doaj.org/article/d82042a167c74c42a972bee0383269e4
Autor:
Deepali K. Bhat, Purevdorj B. Olkhanud, Arunakumar Gangaplara, Fayaz Seifuddin, Mehdi Pirooznia, Angélique Biancotto, Giovanna Fantoni, Corinne Pittman, Berline Francis, Pradeep K. Dagur, Ankit Saxena, J. Philip McCoy, Ruth M. Pfeiffer, Courtney D. Fitzhugh
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Haploidentical hematopoietic stem cell transplantation (haplo-HSCT) is a widely available curative option for patients with sickle cell disease (SCD). Our original non-myeloablative haplo-HSCT trial employing post-transplant (PT) cyclophosphamide had
Externí odkaz:
https://doaj.org/article/24e70ed7cf154c4e8c2147f41d584da8
Autor:
Courtney D. Fitzhugh, Mark C. Walters
Publikováno v:
Blood Advances, Vol 1, Iss 26, Pp 2563-2567 (2017)
Externí odkaz:
https://doaj.org/article/faf6766bf9e246959b4b71fa381f2064
Autor:
Courtney D. Fitzhugh, Matthew M. Hsieh, Tiffani Taylor, Wynona Coles, Katherine Roskom, Delon Wilson, Elizabeth Wright, Neal Jeffries, Christopher J. Gamper, Jonathan Powell, Leo Luznik, John F. Tisdale
Publikováno v:
Blood Advances, Vol 1, Iss 11, Pp 652-661 (2017)
Abstract: Peripheral blood stem cell transplantation (PBSCT) offers a curative option for sickle cell disease (SCD). Although HLA-matched sibling transplantation is promising, the vast majority of patients lack such a donor. We sought to develop a no
Externí odkaz:
https://doaj.org/article/a96a5f8323f4493ab06d444945ba818d
Autor:
Mary Eapen, Ruta Brazauskas, David A. Williams, Mark C. Walters, Andrew St Martin, Benjamin L. Jacobs, Joseph H. Antin, Kira Bona, Sonali Chaudhury, Victoria H. Coleman-Cowger, Nancy L. DiFronzo, Erica B. Esrick, Joshua J. Field, Courtney D. Fitzhugh, Julie Kanter, Neena Kapoor, Donald B. Kohn, Lakshmanan Krishnamurti, Wendy B. London, Michael A. Pulsipher, Sohel Talib, Alexis A. Thompson, Edmund K. Waller, Ted Wun, Mary M. Horowitz
Publikováno v:
Journal of Clinical Oncology. 41:2227-2237
PURPOSE To report the incidence and risk factors for secondary neoplasm after transplantation for sickle cell disease. METHODS Included are 1,096 transplants for sickle cell disease between 1991 and 2016. There were 22 secondary neoplasms. Types incl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4f44a9e2a91572d49b8abe6af4b490cb
https://doi.org/10.1200/jco.22.01203
https://doi.org/10.1200/jco.22.01203
Publikováno v:
Hematology/oncology clinics of North America. 36(6)
Curative therapies for sickle cell disease (SCD) include allogeneic human leukocyte antigen (HLA)- matched sibling and haploidentical hematopoietic cell transplant (HCT), gene therapy, and gene editing. However, comparative trial data that might faci
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a7df491fea4a0ada53185c2cd8178bea
https://pubmed.ncbi.nlm.nih.gov/36400545
https://pubmed.ncbi.nlm.nih.gov/36400545
Publikováno v:
Hematology/Oncology Clinics of North America. 36:1313-1335
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c41cc7457d1f47fc61bc6b7f22b15030
https://doi.org/10.1016/j.hoc.2022.06.007
https://doi.org/10.1016/j.hoc.2022.06.007
Autor:
F. Bernaudin, Damiano Rondelli, Julie Kanter, Teonna L Woolford, Julie A. Panepinto, Courtney D. Fitzhugh, John F. Tisdale, Javier Bolaños-Meade, Shalini Shenoy, Jane S. Hankins, John E. Wagner, Robert I. Liem, Mark C. Walters, Joerg J Meerpohl, M. Hassan Murad
Publikováno v:
Blood Adv
Background: Sickle cell disease (SCD) is a life-limiting inherited hemoglobinopathy that results in significant complications and affects quality of life. Hematopoietic stem cell transplantation (HSCT) is currently the only curative intervention for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dac3d919db2b6834a23ec1ae56e76ad3
https://doi.org/10.1182/bloodadvances.2021004394c
https://doi.org/10.1182/bloodadvances.2021004394c
Autor:
Rialnat A. Lawal, Devdeep Mukherjee, Emily M. Limerick, Wynona Coles, Matthew M. Hsieh, Laura W. Dillon, Christopher S. Hourigan, Courtney D. Fitzhugh
Publikováno v:
Blood. 140(23)
Lawal et al report on a 45-fold increase in secondary hematologic malignancy in 120 patients following hematopoietic stem cell transplantation (HSCT) for sickle cell disease (SCD), comparable to what has been reported following gene therapy. Notably,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f229950bbc95a81cdd6cbddfe0e8cc10
https://pubmed.ncbi.nlm.nih.gov/36044658
https://pubmed.ncbi.nlm.nih.gov/36044658